Cargando…

Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up

Interleukin (IL)-6 and IL-1 blockade showed beneficial results in patients with severe COVID-19 pneumonia and evidence of cytokine release at the early disease stage. Here, we report outcomes of open-label therapy with a combination of blocking IL-6 with tocilizumab 8 mg/kg up to 800 mg and IL-1 rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haibel, Hildrun, Poddubnyy, Denis, Angermair, Stefan, Allers, Kristina, Vahldiek, Janis L., Schumann, Michael, Schneider, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444821/ https://www.ncbi.nlm.nih.gov/pubmed/36071720 http://dx.doi.org/10.1177/1759720X221116405

Ejemplares similares

Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
por: Angriman, Federico, et al.
Publicado: (2021)

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
por: Protopopov, Mikhail, et al.
Publicado: (2017)

Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data
por: Redeker, Imke, et al.
Publicado: (2018)

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis
por: Llop, Maria, et al.
Publicado: (2019)

The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance
por: Bressem, Keno K., et al.
Publicado: (2021)

Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results
por: Poddubnyy, Denis, et al.
Publicado: (2021)

Why not treat human cancer with interleukin-1 blockade?
por: Dinarello, Charles A.
Publicado: (2010)

Interleukin-1 Receptor Blockade in Perinatal Brain Injury
por: Rosenzweig, Jason M., et al.
Publicado: (2014)

Interleukin‐1 blockade treatment decreasing cardiovascular risk
por: Zheng, Zi‐Heng, et al.
Publicado: (2019)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: A case series
por: Peera, Melissa, et al.
Publicado: (2021)

Interleukin 1 blockade withcanakinumab for Hyper IGD syndrome (HIDS)
por: Brunnner, J, et al.
Publicado: (2015)

Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
por: DeSena, Allen D., et al.
Publicado: (2018)

Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade
por: Christersdottir, Tinna, et al.
Publicado: (2019)

Simultaneous targeting of interleukin-1 and interleukin-18 is required for protection against inflammatory and septic shock
por: Berghe, T Vanden, et al.
Publicado: (2014)

Diagnostic importance of pulmonary interleukin-1β and interleukin-8 in ventilator-associated pneumonia
por: Conway Morris, Andrew, et al.
Publicado: (2010)

Interleukin 1 blockade with canacinumab for hyperimmunoglobulin D and periodic fever syndrome
por: Brunner, Juergen, et al.
Publicado: (2014)

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
por: Malcova, Hana, et al.
Publicado: (2021)

The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
por: Torgutalp, Murat, et al.
Publicado: (2022)

Single-agent interleukin-2 in the treatment of metastatic melanoma
por: Petrella, T., et al.
Publicado: (2007)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
por: Cavalli, Giulio, et al.
Publicado: (2017)

Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer
por: Toldo, Stefano, et al.
Publicado: (2017)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

Interleukin‐1 blockade in heart failure: an on‐treatment and off‐treatment cardiorespiratory fitness analysis
por: Moroni, Francesco, et al.
Publicado: (2023)

1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis
por: Kim, Haneul, et al.
Publicado: (2020)

Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review
por: Wang, Ying, et al.
Publicado: (2022)

Relation of α(2)-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis
por: Hoppe, Berthold, et al.
Publicado: (2020)

Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis
por: Hoppe, Berthold, et al.
Publicado: (2021)

Interleukin 1-β, Interleukin-1 Receptor Antagonist, and Interleukin 18 in Children with Acute Spontaneous Urticaria
por: Machura, E., et al.
Publicado: (2013)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2020)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2022)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Combined depletion of interleukin-1 and interleukin-6 does not exceed single depletion of interleukin -1 in TNF-mediated arthritis
por: Hayer, Silvia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p338jbk5hutrici1u6nn6s6j6u